In current clinical development, targeting CD19+ B cell malignancies, which include acute and chronic B-cell leukaemia and B-cell non-Hodgkin lymphomas (NHLs), with anti-CD19 CAR-T cells is one of the most advanced adoptive T-cell therapies and has been approved by the FDA. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.